<DOC>
	<DOCNO>NCT00998582</DOCNO>
	<brief_summary>Recent research suggest use HIV medication abacavir ( Ziagen , co-formulated lamivudine Epzicom ) may increase risk heart disease , though finding multiple study inconsistent . This pilot study examine vascular function , marker heart disease risk , among patient take abacavir part HIV medication randomize : 1 ) switch tenofovir , another HIV medication , 2 ) continue take abacavir .</brief_summary>
	<brief_title>Artery Elasticity After Switch From Epzicom Truvada</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Adult ( ≥18 year ) males nonpregnant female , nonlactating female . HIVinfected participant currently receive fixeddose abacavir/lamivudine base regimen ≥3 month precede screen visit . HIVinfection document positive HIV1 antibody ( confirmatory westernblot ) HIV RNA level ≥1000 copies/mL Two consecutive plasma HIV RNA concentration limit detection clinicalbased assay use HCMC ANW HIV clinic . The 1st HIV RNA concentration must least 3 month prior study entry . Subjects receive lipid lower agent allow ; however , dose medication must stable ≥3 month prior study entry Adequate renal function define calculated creatinine clearance ( CLCr ) ≥50 mL/min accord CockcroftGault formula : MALE : ( 140 age year ) x ( wt kg ) = CLCr ( mL/min ) 72 x ( serum creatinine mg/dL ) FEMALE : ( 140 age year ) x ( wt kg ) x 0.85 = CLCr ( mL/min ) 72 x ( serum creatinine mg/dL ) Negative serum pregnancy test ( female childbearing potential ) Hepatic transaminase ( AST ALT ) ≤ 5 x upper limit normal ( ULN ) . Males female ( childbearing potential ) must agree avoid pregnancy sexual abstinence , utilization highly effective method birth control throughout study period 30 day follow discontinuation study drug ( refer Appendix A definition 'childbearing potential ' 'highly effective method birth control ' ) Subjects know resistance abacavir , lamivudine , tenofovir DF , emtricitabine anytime past ( include limit K65R , L74V/I , M184V/I , thymidine analog mutation ) . A new AIDSdefining condition diagnose ( exception CD4 criterion ) within 30 day baseline Previous therapy agent systemic myelosuppressive , pancreatoxic , hepatotoxic cytotoxic potential within 3 month study entry expectation therapy time enrollment Proven suspect acute hepatitis 30 day prior study entry Receiving ongoing therapy follow ( administration follow medication must discontinue least 30 day prior baseline visit duration study period ) : Nephrotoxic agent ( aminoglycoside antibiotic , amphotericin B , cidofovir , cisplatin , foscarnet , IV pentamidine , agent significant nephrotoxic potential ) Adefovir dipivoxil Probenecid Systemic chemotherapeutic agent ( i.e. , cancer treatment medication ) Systemic corticosteroid Interleukin2 ( IL2 ) Evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication . Current alcohol substance abuse judge investigator potentially interfere subject adherence Malignancy cutaneous Kaposi 's sarcoma ( KS ) basal cell carcinoma . Participants biopsyconfirmed cutaneous KS eligible , must receive systemic therapy KS within 30 day baseline anticipate require systemic therapy study . Active , serious infection ( HIV1 infection ) require parenteral antimicrobial therapy within 15 day prior screen . Prior history significant renal bone disease . Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply dose requirement . Known hypersensitivity study drug , metabolite formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Artery Elasticity</keyword>
	<keyword>Treatment experience</keyword>
</DOC>